Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn:
“More than four years ago, we visited David Wilcox and his team at the Medical College of Wisconsin, where they have spent decades advancing a potential gene therapy cure for GlanzmannThrombasthenia.
Today, we are closer than ever to clinical trials, and we’ll soon be returning to the lab to see firsthand how much progress has been made.
The science is there. The expertise is there.
The biggest barrier to this research reaching patients is funding.
What makes the us so unique as a non-profit in the rare bleeding disorders space is that all donations directly support research to find a cure.
Every donation helps move this promising therapy one step closer to clinical trials.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas LangÖ‰ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge